Over Cancer
Begins Here

Increase The Likelihood of Early Cancer Detection

The TriNetra™-Triumph test is based on a revolutionary technology for early stage cancer detection. The test can indicate likely presence of various common cancers and has the potential to move cancer detection to earlier stages (based on published data)1,2,3,4. The test requires only a simple blood draw.

The Science Behind TriNetra™-Triumph

We published our ground breaking, internationally acclaimed research in 2020, where we reported the discovery of a new ‘Cancer Hallmark’ i.e., Circulating Ensembles of Tumor Associated Cells, which are common in the blood of patients with cancer and are undetectable in completely healthy individuals1,2,5. Circulating Tumor Cells (CTCs) are the essential component of these clusters.
TriNetra™-Triumph is based on this technology and examines blood samples of seemingly healthy individuals for Circulating Tumor Cells (CTCs) and CTC Clusters. Detection of these in blood indicates higher risk of presence of an underlying cancer at the time of testing.

We have developed the TriNetra™-Triumph test to assist health systems in focusing on what is most important: population health, innovation, and providing high-quality healthcare. Work can be done together to potentially improve cancer screening adherence, invite new patients, in this forward-thinking and patient-centered health institution. The TriNetra™-Triumph is a prescription based test which is indicated for asymptomatic individuals with a higher risk of developing cancer, typically those who are above 50 years of age and who do not have prior history of cancer.

An Extensive Testing Experience


Test Ordered by Healthcare Provider


Blood drawn in provider's office or lab


Results are returned to the provider within 12 business days of the specimen being received by Datar Cancer Genetics.

Essential Safety Information

The TriNetra™-Triumph test is advised for use in adults with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer. The TriNetra™-Triumph test should be used in addition to other cancer screening procedures advised by a healthcare professional. The objective of using TriNetra™-Triumph is to identify cancer footprints i.e. CTCs and identify the probable organ / location that may be affected. TriNetra™-Triumph should not be used by pregnant women. TriNetra™-Triumph should never be used as the sole means of diagnosis and the results must always be corroborated by Standard of Care methodologies undertaken through a duly qualified and authorized medical professional.

A healthcare professional should interpret the results in light of the patient’s medical history, physical symptoms, and clinical indicators. A “No Circulating Tumor Cells Detected” test result merely signifies a reduced risk of presence of cancer but it however does not definitively exclude the possibility of cancer. A “Circulating Tumor Cells Detected” test result must necessarily be confirmed by independent diagnostic evaluation using medically accepted Standard of Care techniques (like imaging, for example) and a positive result does not confirm the existence of cancer.

If additional testing does not confirm the presence of cancer, it may indicate that cancer is not currently present (the TriNetra™-Triumph test is ‘false-positive’), and ‘watchful waiting’ is advised subject to the opinion of the individual’s prescribing physician. It is clarified that owing to the diverse biological behavior of cancer and/or the technical limitations of the performance of the test, it is possible for the test findings to be both false-positive (a biological footprint suggestive of cancer is found when cancer is not present) and false-negative (a biological footprint suggestive of cancer is not identified when cancer is present). Prescription Required.

Information from the laboratory about the test

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford, UK, and the College of American Pathologists (CAP) has granted it accreditation. The TriNetra™-Triumph test was developed by Datar Cancer Genetics, and the laboratory has determined the performance parameters of the test. The Food and Drug Administration (US-FDA) has neither approved, endorsed, nor cleared the TriNetra™-Triumph test. High-complexity testing is regulated under the CLIA regime in the Company’s clinical laboratory. The TriNetra™-Triumph test is designed to be used in a clinical setting only.

1. Akolkar et al, Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer, Int J Oncol 2019,
2. Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk, Cancer Prev Res (Phila) (2021) 14 (1): 11–16,
3. Gaya et al., Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol 2021.
4. Limaye et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023; 12: 9116- 9127. doi:10.1002/cam4.5649
5. Lawrence, R., et al. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol 20, 487–500 (2023).

Contact Us

Samples are processed at our CAP-accredited, CLIA-certified facility in:
4 Frederick Sanger Road, The Surrey Research Park, Guildford, Surrey, GU2 7YD, United Kingdom.